{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:18:14Z","timestamp":1791317894159,"version":"4.3.1"},"reference-count":99,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/wco.0b013e3283533a64","type":"journal-article","created":{"date-parts":[[2012,4,6]],"date-time":"2012-04-06T20:38:23Z","timestamp":1333744703000},"page":"231-238","source":"Crossref","is-referenced-by-count":31,"title":["Identifying autoantigens in demyelinating diseases"],"prefix":"10.1097","volume":"25","author":[{"given":"Tobias","family":"Derfuss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Meinl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210206","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1212\/WNL.40.11.1770","article-title":"Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals.","volume":"40","author":"Pette","year":"1990","journal-title":"Neurology"},{"key":"R2-4-20210206","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2008.07.006","article-title":"B- and T-cell responses in multiple sclerosis: novel approaches offer new insights.","volume":"274","author":"Hohlfeld","year":"2008","journal-title":"J Neurol Sci"},{"key":"R4-4-20210206","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/WNL.0b013e318224afde","article-title":"Encephalitis and antibodies to synaptic and neuronal cell surface proteins.","volume":"77","author":"Lancaster","year":"2011","journal-title":"Neurology"},{"key":"R5-4-20210206","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1474-4422(11)70096-5","article-title":"Autoantibodies associated with diseases of the CNS: new developments and future challenges.","volume":"10","author":"Vincent","year":"2011","journal-title":"Lancet Neurol"},{"key":"R6-4-20210206","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00281-009-0179-y","article-title":"Novel approaches for identifying target antigens of autoreactive human B and T cells.","volume":"31","author":"Dornmair","year":"2009","journal-title":"Semin Immunopathol"},{"key":"R7-4-20210206","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1759-1961.2009.00006.x","article-title":"Identifying targets for autoantibodies in CNS inflammation: strategies and achievements.","volume":"1","author":"Meinl","year":"2010","journal-title":"J Clin Exp Neuroimmunol"},{"key":"R8-4-20210206","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"R9-4-20210206","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1084\/jem.20071053","article-title":"Neurofascin as a novel target for autoantibody-mediated axonal injury.","volume":"204","author":"Mathey","year":"2007","journal-title":"J Exp Med"},{"key":"R10-4-20210206","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1073\/pnas.0901496106","article-title":"Contactin-2TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals.","volume":"106","author":"Derfuss","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-4-20210206","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1074\/mcp.M700277-MCP200","article-title":"Transketolase and 2,3-cyclic-nucleotide 3-phosphodiesterase type I isoforms are specifically recognized by IgG autoantibodies in multiple sclerosis patients.","volume":"7","author":"Lovato","year":"2008","journal-title":"Mol Cell Proteomics"},{"key":"R12-4-20210206","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/pmic.200300732","article-title":"New antigenic candidates in multiple sclerosis: identification by serological proteome analysis.","volume":"4","author":"Almeras","year":"2004","journal-title":"Proteomics"},{"key":"R13-4-20210206","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nm1344","article-title":"Lipid microarrays identify key mediators of autoimmune brain inflammation.","volume":"12","author":"Kanter","year":"2006","journal-title":"Nat Med"},{"key":"R14-4-20210206","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.autrev.2009.02.001","article-title":"Multiplexing approaches for autoantibody profiling in multiple sclerosis.","volume":"8","author":"Somers","year":"2009","journal-title":"Autoimmun Rev"},{"key":"R15-4-20210206","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nm0302-295","article-title":"Autoantigen microarrays for multiplex characterization of autoantibody responses.","volume":"8","author":"Robinson","year":"2002","journal-title":"Nat Med"},{"key":"R16-4-20210206","doi-asserted-by":"crossref","first-page":"18889","DOI":"10.1073\/pnas.0806310105","article-title":"Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis.","volume":"105","author":"Quintana","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R17-4-20210206","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.4049\/jimmunol.180.6.3957","article-title":"Autoantibody profiling in multiple sclerosis reveals novel antigenic candidates.","volume":"180","author":"Somers","year":"2008","journal-title":"J Immunol"},{"key":"R18-4-20210206","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ana.410430107","article-title":"Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis.","volume":"43","author":"Archelos","year":"1998","journal-title":"Ann Neurol"},{"key":"R19-4-20210206","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1172\/JCI200523661","article-title":"Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis.","volume":"115","author":"Cepok","year":"2005","journal-title":"J Clin Invest"},{"key":"R20-4-20210206","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneuroim.2011.04.007","article-title":"Identification of peptide targets in neuromyelitis optica.","volume":"236","author":"Yu","year":"2011","journal-title":"J Neuroimmunol"},{"key":"R21-4-20210206","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jneuroim.2011.10.009","article-title":"Intrathecally synthesized IgG in multiple sclerosis cerebrospinal fluid recognizes identical epitopes over time.","volume":"240-","author":"Yu","year":"2011","journal-title":"J Neuroimmunol"},{"key":"R22-4-20210206","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jneuroim.2010.11.007","article-title":"Peptide reactivity between multiple sclerosis (MS) CSF IgG and recombinant antibodies generated from clonally expanded plasma cells in MS CSF.","volume":"233","author":"Yu","year":"2011","journal-title":"J Neuroimmunol"},{"key":"R23-4-20210206","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jneuroim.2007.03.002","article-title":"Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS.","volume":"186","author":"Lambracht-Washington","year":"2007","journal-title":"J Neuroimmunol"},{"key":"R24-4-20210206","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1002\/eji.200737784","article-title":"Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies.","volume":"38","author":"von Budingen","year":"2008","journal-title":"Eur J Immunol"},{"key":"R25-4-20210206","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jneuroim.2005.11.010","article-title":"Specificity of recombinant antibodies generated from multiple sclerosis cerebrospinal fluid probed with a random peptide library.","volume":"172","author":"Yu","year":"2006","journal-title":"J Neuroimmunol"},{"key":"R26-4-20210206","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.autrev.2009.02.030","article-title":"B cell characterization and reactivity analysis in multiple sclerosis.","volume":"8","author":"Fraussen","year":"2009","journal-title":"Autoimmun Rev"},{"key":"R27-4-20210206","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/brain\/awq074","article-title":"T cell recognition of self-antigen presenting cells by protein transfer assay reveals a high frequency of antimyelin T cells in multiple sclerosis.","volume":"133","author":"Bahbouhi","year":"2010","journal-title":"Brain"},{"key":"R28-4-20210206","doi-asserted-by":"crossref","first-page":"12057","DOI":"10.1073\/pnas.0604247103","article-title":"Reconstitution of paired T cell receptor alpha- and beta-chains from microdissected single cells of human inflammatory tissues.","volume":"103","author":"Seitz","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-4-20210206","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.4049\/jimmunol.175.3.1974","article-title":"Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein.","volume":"175","author":"OConnor","year":"2005","journal-title":"J Immunol"},{"key":"R30-4-20210206","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nm1714","article-title":"Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis.","volume":"14","author":"Obermeier","year":"2008","journal-title":"Nat Med"},{"key":"R31-4-20210206","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jneuroim.2011.01.010","article-title":"Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin.","volume":"233","author":"Obermeier","year":"2011","journal-title":"J Neuroimmunol"},{"key":"R32-4-20210206","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ana.21641","article-title":"Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid.","volume":"65","author":"Owens","year":"2009","journal-title":"Ann Neurol"},{"key":"R33-4-20210206","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/B:NEUR.0000010085.91976.a6","article-title":"Antibody-mediated CNS demyelination II. Focal spinal cord lesions induced by implantation of an IgM antisulfatide-secreting hybridoma.","volume":"32","author":"Rosenbluth","year":"2003","journal-title":"J Neurocytol"},{"key":"R34-4-20210206","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2011.08.002","article-title":"Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis.","volume":"238","author":"Brennan","year":"2011","journal-title":"J Neuroimmunol"},{"key":"R35-4-20210206","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1172\/JCI22833","article-title":"Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.","volume":"115","author":"Villar","year":"2005","journal-title":"J Clin Invest"},{"key":"R36-4-20210206","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jns.2005.12.006","article-title":"Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis.","volume":"244","author":"Schwarz","year":"2006","journal-title":"J Neurol Sci"},{"key":"R37-4-20210206","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/1352458508101944","article-title":"Antialpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event.","volume":"15","author":"Freedman","year":"2009","journal-title":"Mult Scler"},{"key":"R38-4-20210206","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jneuroim.2009.07.017","article-title":"Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.","volume":"217","author":"Brettschneider","year":"2009","journal-title":"J Neuroimmunol"},{"key":"R40-4-20210206","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00109-010-0632-3","article-title":"Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury.","volume":"88","author":"Derfuss","year":"2010","journal-title":"J Mol Med"},{"key":"R41-4-20210206","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.1073\/pnas.0903377106","article-title":"The gray aspects of white matter disease in multiple sclerosis.","volume":"106","author":"Steinman","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R42-4-20210206","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMcibr0905482","article-title":"Gray-matter injury in multiple sclerosis.","volume":"361","author":"Rudick","year":"2009","journal-title":"N Engl J Med"},{"key":"R43-4-20210206","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","article-title":"Inflammatory cortical demyelination in early multiple sclerosis.","volume":"365","author":"Lucchinetti","year":"2011","journal-title":"N Engl J Med"},{"key":"R44-4-20210206","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis.","volume":"338","author":"Trapp","year":"1998","journal-title":"N Engl J Med"},{"key":"R45-4-20210206","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"R46-4-20210206","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica.","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"R47-4-20210206","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann Neurol"},{"key":"R48-4-20210206","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic antiaquaporin-4 antibodies in early neuromyelitis optica.","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann Neurol"},{"key":"R49-4-20210206","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbrc.2009.06.085","article-title":"Neuromyelitis optica: passive transfer to rats by human immunoglobulin.","volume":"386","author":"Kinoshita","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"Pt 2","key":"R50-4-20210206","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"R51-4-20210206","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00401-011-0824-0","article-title":"Pathogenic T cell responses against aquaporin 4.","volume":"122","author":"Pohl","year":"2011","journal-title":"Acta Neuropathol"},{"key":"R52-4-20210206","doi-asserted-by":"crossref","first-page":"e16083","DOI":"10.1371\/journal.pone.0016083","article-title":"Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica.","volume":"6","author":"Kalluri","year":"2011","journal-title":"PLoS One"},{"key":"R53-4-20210206","doi-asserted-by":"crossref","first-page":"e15050","DOI":"10.1371\/journal.pone.0015050","article-title":"Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica.","volume":"5","author":"Nelson","year":"2010","journal-title":"PLoS One"},{"key":"R54-4-20210206","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbrc.2010.02.157","article-title":"Antiaquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells.","volume":"394","author":"Kinoshita","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"R55-4-20210206","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","article-title":"Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2.","volume":"205","author":"Hinson","year":"2008","journal-title":"J Exp Med"},{"key":"R56-4-20210206","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes.","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R57-4-20210206","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000303817.82134.da","article-title":"NMO-IgG predicts the outcome of recurrent optic neuritis.","volume":"70","author":"Matiello","year":"2008","journal-title":"Neurology"},{"key":"R58-4-20210206","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","article-title":"CNS aquaporin-4 autoimmunity in children.","volume":"71","author":"McKeon","year":"2008","journal-title":"Neurology"},{"key":"R59-4-20210206","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mus.21197","article-title":"Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica.","volume":"39","author":"McKeon","year":"2009","journal-title":"Muscle Nerve"},{"key":"R60-4-20210206","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease.","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult Scler"},{"key":"R61-4-20210206","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity.","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"R62-4-20210206","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"R63-4-20210206","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"R64-4-20210206","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Antiaquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"key":"R65-4-20210206","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/1352458509104595","article-title":"Aquaporin-4 autoimmune syndrome and antiaquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese.","volume":"15","author":"Matsushita","year":"2009","journal-title":"Mult Scler"},{"key":"R66-4-20210206","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/brain\/awn077","article-title":"Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.","volume":"131","author":"Krumbholz","year":"2008","journal-title":"Brain"},{"key":"R67-4-20210206","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0b013e3181c919ee","article-title":"B-cell activating factor of the TNF family is upregulated in neuromyelitis optica.","volume":"74","author":"Okada","year":"2010","journal-title":"Neurology"},{"key":"R68-4-20210206","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R69-4-20210206","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R70-4-20210206","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4049\/jimmunol.1102321","article-title":"Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors.","volume":"188","author":"Kreuzaler","year":"2012","journal-title":"J Immunol"},{"key":"R72-4-20210206","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.","volume":"13","author":"OConnor","year":"2007","journal-title":"Nat Med"},{"key":"R73-4-20210206","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis.","volume":"77","author":"Probstel","year":"2011","journal-title":"Neurology"},{"key":"R74-4-20210206","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.4049\/jimmunol.0801888","article-title":"Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis.","volume":"183","author":"McLaughlin","year":"2009","journal-title":"J Immunol"},{"key":"R75-4-20210206","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease.","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol"},{"key":"R76-4-20210206","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases.","volume":"138","author":"Di Pauli","year":"2011","journal-title":"Clin Immunol"},{"key":"R77-4-20210206","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1352458510389220","article-title":"Highly reactive antimyelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children.","volume":"17","author":"Lalive","year":"2011","journal-title":"Mult Scler"},{"key":"R78-4-20210206","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.","volume":"8","author":"Mader","year":"2011","journal-title":"J Neuroinflammation"},{"key":"R79-4-20210206","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1172\/JCI28330","article-title":"Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cellB cell cooperation.","volume":"116","author":"Krishnamoorthy","year":"2006","journal-title":"J Clin Invest"},{"key":"R80-4-20210206","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.188.1.169","article-title":"B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice.","volume":"188","author":"Litzenburger","year":"1998","journal-title":"J Exp Med"},{"key":"R81-4-20210206","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.20090299","article-title":"Spontaneous relapsing-remitting EAE in the SJLJ mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.","volume":"206","author":"Pollinger","year":"2009","journal-title":"J Exp Med"},{"key":"R82-4-20210206","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nrneurol.2011.45","article-title":"White matter disease: roles of anti-MOG antibodies in demyelinating diseases.","volume":"7","author":"Olsson","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"R83-4-20210206","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1056\/NEJMoa063602","article-title":"Lack of association between antimyelin antibodies and progression to multiple sclerosis.","volume":"356","author":"Kuhle","year":"2007","journal-title":"N Engl J Med"},{"key":"R84-4-20210206","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.","volume":"349","author":"Berger","year":"2003","journal-title":"N Engl J Med"},{"key":"R85-4-20210206","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0165-5728(00)00462-8","article-title":"The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls.","volume":"114","author":"Haase","year":"2001","journal-title":"J Neuroimmunol"},{"key":"R86-4-20210206","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1073\/pnas.0510672103","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.","volume":"103","author":"Lalive","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R87-4-20210206","doi-asserted-by":"crossref","first-page":"19057","DOI":"10.1073\/pnas.0607242103","article-title":"Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.","volume":"103","author":"Zhou","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R88-4-20210206","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4049\/jimmunol.1001543","article-title":"Increased frequencies of myelin oligodendrocyte glycoproteinMHC class II-binding CD4 cells in patients with multiple sclerosis.","volume":"187","author":"Raddassi","year":"2011","journal-title":"J Immunol"},{"key":"R89-4-20210206","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1172\/JCI119331","article-title":"Diversity and plasticity of self recognition during the development of multiple sclerosis.","volume":"99","author":"Tuohy","year":"1997","journal-title":"J Clin Invest"},{"key":"R90-4-20210206","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/brain\/awl075","article-title":"Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.","volume":"129","author":"Gold","year":"2006","journal-title":"Brain"},{"key":"R91-4-20210206","first-page":"445","article-title":"Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques.","volume":"150","author":"Meinl","year":"1997","journal-title":"Am J Pathol"},{"key":"R92-4-20210206","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/15525","article-title":"A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.","volume":"23","author":"Madsen","year":"1999","journal-title":"Nat Genet"},{"key":"R93-4-20210206","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/archneur.64.10.nct70002","article-title":"Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 12 trial.","volume":"64","author":"Bar-Or","year":"2007","journal-title":"Arch Neurol"},{"key":"R94-4-20210206","first-page":"T289","article-title":"MRI results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis.","volume":"42","author":"Francis","year":"1997","journal-title":"Ann Neurol"},{"key":"R95-4-20210206","first-page":"T262","article-title":"Clinical results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis.","volume":"42","author":"Panitch","year":"1997","journal-title":"Ann Neurol"},{"key":"R96-4-20210206","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/80525","article-title":"Induction of a nonencephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.","volume":"6","author":"Kappos","year":"2000","journal-title":"Nat Med"},{"key":"R97-4-20210206","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/80516","article-title":"Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.","volume":"6","author":"Bielekova","year":"2000","journal-title":"Nat Med"},{"key":"R98-4-20210206","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1126\/science.7680493","article-title":"Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.","volume":"259","author":"Weiner","year":"1993","journal-title":"Science"},{"key":"R99-4-20210206","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e318233b240","article-title":"A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.","volume":"77","author":"Freedman","year":"2011","journal-title":"Neurology"},{"key":"R100-4-20210206","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ana.22219","article-title":"Immune regulation of multiple sclerosis by transdermally applied myelin peptides.","volume":"68","author":"Jurynczyk","year":"2010","journal-title":"Ann Neurol"},{"key":"R101-4-20210206","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1468-1331.2006.01533.x","article-title":"Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.","volume":"13","author":"Warren","year":"2006","journal-title":"Eur J Neurol"},{"key":"R102-4-20210206","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-510X(97)00130-5","article-title":"Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis.","volume":"152","author":"Warren","year":"1997","journal-title":"J Neurol Sci"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WCO.0b013e3283533a64","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T08:12:06Z","timestamp":1620979926000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019052-201206000-00004"}},"subtitle":["valuable clues to diagnosis and treatment?"],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e3283533a64","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}